SCHEMBL3435491

SCHEMBL3435491

COc1cc(Cl)ccc1-c1nc(C)c(CO)s1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSP90AA1 P07900 1/20 0.44
HSP90AB1 P08238 1/20 0.44
LMNA P02545 4/20 0.43
MAPT P10636 7/20 0.42
TP53 P04637 2/20 0.42
KDM4E B2RXH2 2/20 0.41
IMPDH2 P12268 1/20 0.39
PSEN1 P49768 1/20 0.39
PSEN2 P49810 1/20 0.39
APH1B Q8WW43 1/20 0.39
NCSTN Q92542 1/20 0.39
APH1A Q96BI3 1/20 0.39
PSENEN Q9NZ42 1/20 0.39
ALOX5 P09917 1/20 0.38
CRHR1 P34998 3/20 0.37
GUSB P08236 1/20 0.37
ALDH1A1 P00352 1/20 0.36
CNR1 P21554 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.36
CTSA P10619 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19936773 0.88 HSP90AA1 (0.45) HSP90AA1HSP90AB1LMNAMAPTTP53
SCHEMBL3436699 0.86 MAPT (0.42) LMNAMAPTTP53KDM4EALOX5
SCHEMBL3436700 0.85 CYP1A1 (0.51) LMNAMAPTTP53KDM4ECRHR1
SCHEMBL14800309 0.85 PTGDR2 (0.49) LMNAMAPTTP53KDM4EALDH1A1
SCHEMBL3436683 0.85 KDM4E (0.40) HSP90AA1HSP90AB1LMNAMAPTKDM4E
SCHEMBL3436690 0.83 KDM4E (0.42) LMNAMAPTTP53KDM4ECRHR1
SCHEMBL3436654 0.83 KDM4E (0.38) HSP90AA1HSP90AB1LMNAMAPTKDM4E
SCHEMBL3436483 0.82 MAPT (0.46) HSP90AA1HSP90AB1LMNAMAPTTP53
SCHEMBL19936536 0.82 HSP90AA1 (0.49) HSP90AA1HSP90AB1MAPTKDM4ECRHR1
SCHEMBL10049417 0.81 LMNA (0.48) HSP90AA1HSP90AB1LMNAMAPTTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2594555-B1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA PHARM CO LTD (JP) 2018-03-07 EP disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
US-9200008-B2 Heterocyclic compound and p27Kip1 degradation inhibitor ASKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-01 US disclosed
EP-2594555-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR ASKA Pharmaceutical Co., Ltd. (JP) 2013-05-22 EP disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR ASKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-28 US disclosed
WO-2012002527-A1 HETEROCYCLIC COMPOUND, AND p27 KIP1 DEGRADATION INHIBITOR あすか製薬株式会社 (JP) 2012-01-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130079306-A1 HETEROCYCLIC COMPOUND AND p27Kip1 DEGRADATION INHIBITOR CDKN1A, SKP2, CCNI HSP90AA1 2419/4885HSP90AB1 2147/4885LMNA 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.